Brussels + 32.2.645.14.27

Luca Salernitano advises international clients on EU and national regulatory matters in the life sciences arena, particularly involving pharmaceuticals, medical devices, cosmetics, and food products. He assists companies in the entire lifecycle of products, from early development stages, to manufacturing, marketing, and post-marketing issues.

Luca has significant litigation and dispute resolution experience before the Court of Justice of the European Union as well as Italian courts. He also has worked on corporate/transactional, product liability, and data privacy matters.

Luca has spoken at national and international events on pharmaceuticals and food products and has contributed to articles regarding pharmaceutical regulations.


  • STERIS acquires Cantel Medical for $3.6 billionJones Day advised STERIS plc in its acquisition of Cantel Medical Corp, a global provider of infection prevention products and services primarily to endoscopy and dental customers, for $3.6 billion.
  • Sumitovant Biopharma acquires remaining stake in Urovant SciencesJones Day advised Sumitovant Biopharma in its acquisition of all of the outstanding shares of Urovant Sciences Ltd. not already owned by Sumitovant at a price of $16.25 per share in cash.
  • Sumitomo Dainippon Pharma acquires late stage biopharma companies and forms alliance with Roivant Sciences Ltd. worth $3 billionJones Day advised Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo") in an acquisition of late stage biopharma companies and formation of alliance with Roivant Sciences Ltd.